Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cobimetinib + Vemurafenib & Melanoma (cutaneous) (BRAF m), the FDA approved Cobimetinib + Vemurafenib for the treatment of patients with unresectable or metastatic Melanoma (cutaneous) (BRAF m), based on the phase III coBRIM trial. The approval was granted in 2015, and the indication is for advanced or metastatic cutaneous melanoma that is BRAF‑V600E– or V60**0K**‑positive, as confirmed by an FDA‑approved test (e.g., Cobas BRAF V600 Mutation Test).
The [European Commission has authorized](brain://QMGe2vnxWkWiArAahJp9a…